Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
All news
Biotechnology
The US Food and Drug Administration yesterday approved a supplemental application for Epclusa (sofosbuvir and velpatasvir) to treat hepatitis C virus (HCV) in children aged six years and older or weighing at least 37 pounds (17 kilograms) with any of the six HCV genotypes—or strains—without cirrhosis (liver disease) or with mild cirrhosis. 20 March 2020
Biotechnology
A US court in Delaware has ruled in favor of Oxford Nanopore Technologies, in patent litigation between the UK biotech and California’s Pacific Biosciences (PacBio). 19 March 2020
Biotechnology
US biotech firm Dragonfly Therapeutics today announced an expansion of its strategic collaboration with Merck & Co to discover, develop and commercialize a number of Dragonfly's candidate natural killer (NK) cell engager immunotherapies for oncology, infectious disease, and immune disorders. 19 March 2020
Biotechnology
China’s National Medical Products Administration (NMPA) has granted marketing authorization for Ameile (almonertinib, previously also known as HS-10296) once daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), who have progressed on or after other EGFR tyrosine kinase inhibitor (TKI) therapy. 19 March 2020
Biotechnology
As many drugmakers are looking at repurposing existing drugs to help alleviate the coronavirus crisis, Swiss pharma giant Roche says it is in talks with the US medicines regulator for its blockbuster immunosuppressive drug. 19 March 2020
Biotechnology
Patients may one day be able to drop a COVID-19 vaccine in the Amazon basket, if British biotech firm Stabilitech BioPharma has its way. 19 March 2020
Biotechnology
With evidence from Chinese authorities suggesting that Avigan (favipiravir) could be effective in treating the symptoms of COVID-19, shares in the drug’s developer, Fujifilm Toyama Chemical, have surged. 19 March 2020
Biotechnology
Switzerland-incorporated Roivant Sciences says it is engaged with regulators in the USA, Europe, and Asia to rapidly advance the clinical development of gimsilumab for the treatment of acute respiratory distress syndrome (ARDS) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. 19 March 2020
Biotechnology
Russian biotech company Biocad says it has started research in order to create an mRNA vaccine against SARS-COV-2 (coronavirus). 19 March 2020
Biotechnology
Impact BioMedical has said that computational models indicate that its Linebacker and Equivir compounds successfully inhibit infection by SARS-CoV-2, the virus responsible for the COVID-19 outbreak. 18 March 2020
Biotechnology
Tianjin, China-based biotech CanSino Biologics has entered into Phase I trials for its COVID-19 vaccine candidate, Ad5-nCoV. 18 March 2020
Biotechnology
A tidal wave of media speculation involving small German mRNA-based drug specialist CureVac and its management changes, the coronavirus and US President Donald Trump, led the company to hold a media call on Tuesday evening as it could not respond to all the individual reporter inquiries. 18 March 2020
Biotechnology
US precision medicines company IDEAYA Biosciences saw its shares leap 15.5% to $3.50 by mid-day, after it revealed a clinical trial collaboration with pharma giant Pfizer. 18 March 2020
Biotechnology
Danish diabetes care giant Novo Nordisk has announced that two Phase III clinical trials and one Phase II trial for concizumab have been paused, due to: “non-fatal thrombotic events” in three patients. 18 March 2020
Biotechnology
UK gene and cell therapy company Oxford Biomedica has signed a new licence and clinical supply agreement (LSA) with Juno Therapeutics, a part of Bristol-Myers Squibb. 18 March 2020
Biotechnology
Ophthalmic gene therapy company Horama has announced an exclusive licensing agreement for global rights to a program targeting retinal dystrophy associated with pathogenic CRB1 gene mutations. 18 March 2020
Biotechnology
US biotech Moderna on Monday announced that the first participant has been dosed in the Phase I study of its mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2). 17 March 2020
Biotechnology
A new collaboration has been launched between New York-based Pfizer and German biopharmaceutical company BioNTech. 17 March 2020
Biotechnology
US biotech company Regeneron has provided an update on its coronavirus (COVID-19) antibody program. 17 March 2020
Biotechnology
UK-based drugmaker AstraZeneca has reported data from the final analysis of the Phase III CASPIAN trial in lung cancer. 17 March 2020
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze